Search Results
May 27, 2026, 17:00 ET Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
https://pp.jazzpharma.com/pi/ziihera.en.USPI.pdf ® TEVIMBRA (tislelizumab) is a registered trademark of BeOne Medicines.About Jazz PharmaceuticalsJazz
More news about: Jazz Pharmaceuticals plc
May 26, 2026, 17:12 ET 美納里尼集團於 2026 年美國臨床腫瘤學會 (ASCO) 年會上發佈新數據
大會將發表一項第 1/2 期 ELEVATE 研究的全新數據，探索埃拉司群與卡帕塞替尼聯合療法，應用於 ER+/HER2-（雌激素受體陽性/第 2 型人類表皮生長因子受體陰性）且伴隨 PI3K/AKT/PTEN 通路變異的轉移性乳癌患者時的安全性及初步療效。 會上將分享更多關於埃拉司群於晚期治療階段中的聯合療法研究詳情，包括：ADELA（與依維莫司 (everolimus) 聯合治療的關鍵第 3 期研究）；ELECTRA（與阿貝馬西利 (abemaciclib) 聯合治療腦轉移患者的第
More news about: Menarini Industrie Farmaceutiche Riunite
May 26, 2026, 16:45 ET Menarini Group annuncia nuovi dati alla riunione annuale dell'American Society of Clinical Oncology (ASCO) 2026
l'efficacia preliminare di elacestrant in combinazione con capivasertib in pazienti con carcinoma mammario metastatico (mBC) alterato dalla via ER+/HER2- PI3K/AKT/PTEN- dallo studio ELEVATE di fase 1/2. Ulteriori dettagli sugli studi in corso su elacestrant in combinazione, nel contesto avanzato, saranno
More news about: Menarini Industrie Farmaceutiche Riunite
May 26, 2026, 08:10 ET Menarini Group、American Society of Clinical Oncology (ASCO)の2026年年次総会で新データを発表
ER+/HER2- PI3K/AKT/PTEN- 経路を変化させた転移性乳癌（mBC）患者におけるエラセストラント とカピバセルチブ の併用療法 の安全性と予備的有効性を探る新たなデータが、第 1/2 相ELEVATE 試験より発表されます。現在進行中のエラセストラント併用療法の詳細について、ADELA（エベロリムスとの
More news about: Menarini Industrie Farmaceutiche Riunite
May 26, 2026, 07:30 ET Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
preclinical study in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research ("AACR"), demonstrating that dual PI3K/mTOR inhibition with paxalisib altered tumor cell state and immune signaling in preclinical TNBC models. TNBC accounts for approximately 15 to 20 percent
More news about: Kazia Therapeutics Limited
May 25, 2026, 11:56 ET 메나리니 그룹, 2026 미국임상종양학회(ASCO) 연례회의에서 새로운 데이터 발표
1/2상 ELEVATE 시험에서 ER+/HER2- PI3K/AKT/PTEN 경로 변이가 있는 전이성 유방암(mBC) 환자를 대상으로 카피바세르팁과 병용한 엘라세스트란트의 안전성 및 예비 유효성을 탐색한 신규 데이터가 발표된다. 진행성 환경에서 엘라세스트란트 병용요법을 평가하는 진행 중인 시험들에 대한 추가 세부 내용도 공유될
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 09:47 ET Menarini anuncia nuevos datos en la reunión anual de la Sociedad Americana de Oncología Clínica (ASCO) 2026
preliminar de elacestrant en combinación con capivasertib en pacientes con cáncer de mama metastásico (mBC) con alteraciones en la vía ER+/HER2- PI3K/AKT/PTEN-, provenientes del estudio ELEVATE de fase 1/2. Se compartirán detalles adicionales sobre estudios en curso de elacestrant en combinación con capivasertib
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 08:13 ET Menarini Group gibt neue Daten auf der Jahrestagung 2026 der American Society of Clinical Oncology (ASCO) bekannt
Es werden neue Daten zur Sicherheit und vorläufigen Wirksamkeit von Elacestrant in Kombination mit Capivasertib bei Patientinnen mit ER+/HER2- PI3K/AKT/PTEN-verändertem metastasiertem Brustkrebs (mBC) aus der Phase-1/2-Studie ELEVATE vorgestellt. Weitere Einzelheiten zu laufenden Studien über die
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 08:06 ET Menarini Group annonce de nouvelles données lors de la réunion annuelle 2026 de l'American Society of Clinical Oncology (ASCO)
de l'elacestrant en combinaison avec le capivasertib chez les patientes atteintes d'un cancer du sein métastatique (mBC) altéré par la voie ER+/HER2- PI3K/AKT/PTEN- seront présentées à partir de l'étude de phase 1/2 ELEVATE . Des détails supplémentaires sur les études en cours sur l'association d'elacestrant,
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 08:03 ET Menarini Group Anuncia Novos Dados na Reunião Anual da American Society of Clinical Oncology (ASCO) 2026
e a eficácia preliminar do elacestranto em combinação com capivasertibe em pacientes com câncer de mama metastático (mBC) alterado pela via ER+/HER2- PI3K/AKT/PTEN- do estudo ELEVATE de fase 1/2 serão apresentados. Detalhes adicionais sobre os estudos em andamento do elacestranto em combinação, no cenário
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 07:46 ET El Grupo Menarini anuncia nuevos datos en la Reunión Anual de la Sociedad Estadounidense de Oncología Clínica (asco) 2026
la eficacia preliminar de elacestrant en combinación con capivasertib en pacientes con cáncer de mama metastásico (CMM) alterado por la vía ER+/HER2- PI3K/AKT/PTEN- del estudio ELEVATE de fase 1/2. Se compartirán detalles adicionales sobre los estudios en curso de elacestrant en combinación, en el entorno
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 06:44 ET Menarini Group Announces New Data at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
New data exploring the safety and preliminary efficacy of elacestrant in combination with capivasertib in patients with ER+/HER2- PI3K/AKT/PTEN- pathway altered metastatic breast cancer (mBC) from the phase 1/2 ELEVATE study will be presented. Additional details on ongoing studies
More news about: Menarini Industrie Farmaceutiche Riunite
May 22, 2026, 22:54 ET La bêta ouverte de Ragnarok Zero: Global de Gravity Game Unite est désormais en ligne et les joueurs du monde entier répondent présent !
pointe de fraîcheurRagnarok Zero: Global offre une première impression soignée en modernisant les éléments visuels emblématiques de la PI Ragnarok, notamment ses icônes, son lanceur et ses skins dédiés.Le jeu offre également une interface intuitive qui permet aux joueurs de comprendre
More news about: Gravity Game Unite SDN. BHD.
May 22, 2026, 22:17 ET MINISO ouvre sa première boutique en Suisse et présente à Berne son expérience de la vente au détail axée sur la PI
l'expérience de consommation distinctive de MINISO, axée sur la PI. En tant que plateforme mondiale d'exploitation de la propriété intellectuelle, MINISO rassemble en une seule destination dynamique des PI sous licence mondialement appréciées, des PI exclusives, une culture de collection, des produits à la
More news about: MINISO
May 22, 2026, 10:16 ET Texaský institut pro léčbu srdečních arytmií při St. David's Medical Center pořádá mezinárodní konferenci o komplexních srdečních arytmiích
content:https://www.prnewswire.com/news-releases/texasky-institut-pro-lebu-srdenich-arytmii-pi-st-davids-medical-center-poada-mezinarodni-konferenci-o-komplexnich-srdenich-arytmiich-302780197.html
More news about: Texas Cardiac Arrhythmia Institute at St. David’s Medical Center
May 21, 2026, 17:00 ET Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
pan-mutant selective PI3Kα inhibitor)A Phase 1/2 trial of tersolisib(LY4064809/STX-478), a pan-mutant-selective PI3Kα inhibitor (PI3Kαi), in PIK3CA-mutant
More news about: Eli Lilly and Company
May 20, 2026, 23:53 ET 爆款「tomica GARAGE」升級為智能款；「tomica GARAGE Smart STONE GRAY Standard Edition」將於2026年7月中旬發售
Standard Edition」（建議零售價：7700日元含稅）。 圖片1：https://cdn.kyodonewsprwire.jp/prwfile/release/M000076/202604278228/_prw_PI1fl_w60xAH3I.jpg*本產品不包含多美卡(TOMICA)（迷你玩具車）。該產品將在日本全國的玩具專賣店、百貨商場玩具區及大型零售店、TOMICA/PLARAIL產品專賣店「TOMICA
More news about: TOMY Company, Ltd.
May 20, 2026, 21:24 ET Skalierbare Stromversorgungslösungen von ROHM für Automobil-SoCs; Kombination aus PMIC und DrMOS für ein optimales SoC-Stromversorgungsdesign und zukünftige Leistungsfähigkeit
https://cdn.kyodonewsprwire.jp/prwfile/release/M106254/202605128856/_prw_PI1fl_5304RZD9.jpg Die PMICs sind in QFN-Gehäusen mit benetzbaren Flanken untergebracht, während der DrMOS in einem
More news about: ROHM Co., Ltd.
May 20, 2026, 08:49 ET Vertical Pharmaceuticals Partners with Medfinder to Help Patients Find Relexxii® During Ongoing ADHD Medication Shortages
relexxii.com/pi. For U.S. residents only. About Medfinder
More news about: Alora Pharmaceuticals, LLC
May 19, 2026, 16:38 ET VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME
Salmonella FliC flagellin engineered to activate TLR5 selectively. Upon engagement, Entolimod likely triggers NF-κB-dependent signaling to stimulate G-CSF, PI3K, and IL-6 production, among others, to promote multi-tissue cytoprotection, and inhibit apoptosis in radiosensitive hematopoietic and gastrointestinal
More news about: Valion Bio, Inc.
May 19, 2026, 15:14 ET BIMZELX® (bimekizumab-bkzx) demonstrates superior efficacy over SKYRIZI® (risankizumab-rzaa) in psoriatic arthritis: BE BOLD Week 16 data
psoriatic arthritis: 16-week results from a head-to-head, multicentre, randomised, phase 3b study. 2026. EULAR. #LB0001.BIMZELX (bimekizumab) U.S. PI. https://www.ucb-usa.com/Innovation/Products/BIMZELX. Last accessed:
More news about: UCB
May 19, 2026, 15:00 ET A TEAM WITH NO HOME: REDPOCKET MOBILES TO LAUNCH ALL-ACCESS BASEBALL DOCUSERIES
https://www.youtube.com/watch?v=gr2H1GA72PIWith episodes dropping throughout the summer, the series will follow the Mobiles everywhere from clubhouses and dugouts to
More news about: Red Pocket Mobile
May 19, 2026, 11:29 ET Samsung México presenta cómo será el anfitrión de la mejor visión del juego con sus nuevas pantallas 2026
estilo.José Antonio Pontón estuvo a cargo de mostrar las capacidades de OLED; Carlos Vassan presentó la nueva generación de Micro RGB; Charly Pi profundizó en la experiencia visual de Mini LED; Aura López destacó la integración entre arte y tecnología de The Frame Pro; mientras que Padrino presentó
More news about: Samsung Mexico
May 19, 2026, 10:00 ET MEKanistic Therapeutics Announces FDA Clearance of IND for MTX-531, Enabling Phase 1 Trial in Advanced Solid Tumors
inhibition of EGFR and PI3K, durable tumor regressions and a differentiated tolerability profile. IND-enabling toxicology studies were supported through the National Cancer Institute's Experimental Therapeutics, or NExT, Program.About MTX-531MTX-531 is a dual inhibitor of PI3K and EGFR designed
More news about: MEKanistic Therapeutics, Inc.
May 19, 2026, 08:45 ET Tattu Launches 5.0 Smart Battery Platform as Heavy-Lift Drones Demand Faster Charging and Smarter Fleet Power Management
maintenance and manage power assets with greater confidence."Tattu 5.0 represents our understanding of where the UAV industry is heading," said the Dr. Pi, R&D Expert at Grepow. "As heavy-lift drones become larger and more capable, the battery system must support not only power output, but also charging
More news about: Tattu